Quantum physics has the answer to making better holograms

Once, holograms were just a scientific curiosity. But thanks to the rapid development of lasers, they have gradually moved center stage, appearing on the security imagery for credit cards and banknotes, in science fiction movies – most memorably Star Wars – and even “live” on stage when long-dead rapper Tupac reincarnated for fans at the Coachella music festival in 2012. Holography is the photographic process of recording light that is scattered by an object and presenting it in a three-dimensional way. Invented in the early 1950s by the Hungarian-British physicist Dennis Gabor, the discovery later earned him the Nobel Prize…

This story continues at The Next Web

Related Articles

Lemurs might hold the key to human hibernation necessary for Mars missions

Science fiction is shifting into reality. With humanity’s plans to return to the moon this decade and further ambitions to travel to Mars in the next, we need to figure out how to keep astronauts healthy for these years-long missions. One solution long championed by science fiction is suspended animation, or putting humans in a hibernation-like sleep for the duration of travel time. We can turn to nature for guidance and a potential solution to this challenge. It’s cold and dark out there Space is unforgiving. In this freezing void of darkness, there is no oxygen, no gravity , and… This story continues at The Next Web

3 reasons why almost every VC investor passed on Zoom

We now live in a Zoom world. Since founding the now-iconic video-conferencing company in 2011, Eric Yuan has elevated Zoom to one of the most successful SaaS businesses in recent history. With 400,000 paying customers, $600+ million in quarterly revenue, and a market cap north of $100 billion, Zoom is ubiquitous in post-pandemic 2020.  But when Yuan was raising his Series A round back in 2012, dozens of institutional venture capital firms — including those focused on early-stage, cloud, and mobile deals — passed on Zoom. Why, and what can investors and entrepreneurs learn from these reasons? Zoom’s early days… This story continues at The Next Web

We might see an Apple car this decade — here’s what we know

After years of speculation and long spells of silence, we finally got a bunch of Apple Car-related news last night. First, Bloomberg reported that Apple has a small dedicated team developing drive systems, vehicle interior, and external car body designs — but it’ll take at least half a decade to ship a unit.  Separately, Hyundai said in a statement to CNBC that it’s in early talks with the iPhone maker to build a car for it: We understand that Apple is in discussion with a variety of global automakers, including Hyundai Motor. As the discussion is at its early stage, nothing… This story continues at The Next WebOr just read more coverage about: Apple

Big pharma is using AI and machine learning in drug discovery and development to save lives

Summary List PlacementThe pharmaceutical industry has been slow-moving when it comes to adopting digital health technology, and pharma companies overall have taken a long time to implement AI and machine learning strategies — making broad-scale digital transformation difficult.

There is ample opportunity for drug discovery and development, but it relies on the ability of companies to implement advanced health tech into everyday strategies. 
While the healthcare industry is rapidly adopting digital tech, the pharma industry is lagging on digital maturity, and any measures even early movers are taking to catch up are patchworked due to a lack of strategy and digital-focused leadership.
AI & Machine Learning in the Drug Development Process
An incredible amount of time and money goes into drug development — bringing a drug to market costs about $2.8 billion dollars over 12+ years, according to Taconic Biosciences’ tally.  
Utilizing AI and machine learning can help at every stage of the drug discovery process. Healthcare AI startups were able to raise over  $2 billion in Q3 2020, and those using AI to streamline the drug making process were the recipients of some of the heftiest sums compared with startups deploying the tech in other healthcare segments.
AI in Drug Discovery (Phase I)
The drug discovery process ranges from reading and analyzing already existing literature, to testing the ways potential drugs interact with targets. According to Insider Intelligence’ AI in Drug Discovery and Development report, AI could curb drug discovery costs for companies by as much as 70%.
AI in Preclinical Development (Phase 2)
The preclinical development phase of drug discovery involves testing potential drug targets on animal models. Utilizing AI during this phase could help trials run smoothly and enable researchers to more quickly and successfully predict how a drug might interact with the animal model.
AI in Clinical Trials (Phase 3)
After making it through the preclinical development phase, and receiving approval from the FDA, researchers begin testing the drug with human participants. Overall, this is a four-phase process and usually considered the longest and most expensive stage in the drug making journey. 
AI can facilitate participant monitoring during clinical trials—generating a larger set of data more quickly—and aid in participant retention by personalizing the trial experience. 
Pharma Investments in AI
Big tech investments in pharma are at an all time high. Specifically, big tech firms with a broad range of AI and cloud solutions make valuable partners to drugmakers, which have varied needs when it comes to AI.

For example, Moderna leverages Amazon’s AWS cloud platform to speed up its drug development process. And while Moderna has recently made headlines as a top contestant in the race to develop a coronavirus vaccine, the company should also be recognized for its success in developing a cancer vaccine in just 40 days while leaning on AWS. 
Moderna is just one example of the many pharma companies taking advantage of Big Tech’s growing interest in the digital health industry. And Insider Intelligence expects Big Tech to continue using their AI brawn to forge pharma tie-ups.
Here are the companies analyzed in the report:

AbbVie
Amazon
Apple
AstraZeneca
Atomwise
Biofourmis
Eli Lilly
Exscientia
Google
Insilico
Litmus Health
Microsoft
Moderna
Novartis
Otsuka
Pfizer
Recursion Pharmaceuticals
Repurpose.AI
Roche
Sanofi
TriNetX
Verily
Verisim
XtalPi

Interested in getting the full report? Here’s how you can gain access:

Join other Insider Intelligence clients who receive this report, along with thousands of other Digital Health forecasts, briefings, charts, and research reports to their inboxes. > > Become a Client
Purchase the individual report from our store. > > Buy The Report Here
Join the conversation about this story »

Responses

Your email address will not be published. Required fields are marked *

Receive the latest news

Subscribe To Our Weekly Newsletter

Get notified about chronicles from TreatMyBrand directly in your inbox